Meclofenoxate

Meclofenoxate

SCHEMBL147339

CN(C)CCOC(=O)COc1ccc(Cl)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2C19 P33261 1/20 1.00
BLM P54132 1/20 0.97
PMP22 Q01453 1/20 0.97
SMN1; SMN2 Q16637 2/20 0.74
HRH3 Q9Y5N1 1/20 0.62
TSHR P16473 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
PTGS2 P35354 1/20 0.51
ALDH1A1 P00352 4/20 0.50
GAA P10253 2/20 0.50
MAPT P10636 1/20 0.50
POLB P06746 1/20 0.50
KDM4E B2RXH2 2/20 0.49
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Meclofenoxate SCHEMBL28363047 0.98 CYP1A2 (0.97) CYP1A2CYP3A4CYP2C19BLMPMP22
Meclofenoxate SCHEMBL218322 0.98 BLM (1.00) CYP1A2CYP3A4CYP2C19BLMPMP22
Meclofenoxate SCHEMBL1172142 0.97 CYP1A2 (0.94) CYP1A2CYP3A4CYP2C19BLMPMP22
SCHEMBL12742257 0.86 SMN1; SMN2 (0.97) CYP1A2CYP3A4CYP2C19BLMPMP22
SCHEMBL31122986 0.84 SMN1; SMN2 (0.73) CYP1A2CYP3A4CYP2C19BLMPMP22
SCHEMBL28252143 0.83 CYP1A2 (0.70) CYP1A2CYP3A4CYP2C19BLMPMP22
SCHEMBL6598625 0.82 HRH3 (0.69) CYP1A2CYP3A4CYP2C19BLMPMP22
SCHEMBL21384542 0.81 CYP1A2 (0.68) CYP1A2CYP3A4CYP2C19BLMPMP22
SCHEMBL25391970 0.80 TDP1 (0.70) CYP1A2CYP3A4CYP2C19BLMPMP22
SCHEMBL6599620 0.80 HRH3 (0.67) CYP1A2CYP3A4CYP2C19BLMPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4722714-A1 SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) Korea Institute of Science and Technology (KR) 2026-04-08 EP claimed
US-20250152601-A1 Compositions and Methods for the Treatment of Sexual Dysfunctions THE JONATHAN HURT LIVING TRUST (US) 2025-05-15 US claimed
CN-119015253-A Water-medicine complex and preparation method thereof 天津医科大学第二医院 2024-11-26 CN claimed
CN-118355836-A Planting method for improving rice yield per unit 长沙市农业技术推广中心(湖南省农业广播电视学校长沙市分校) 2024-07-19 CN claimed
US-20240043473-A1 NOOTROPIC PEPTIDES FOR TREATING LYSOSOMAL STORAGE DISEASES PHOENIX NEST INC. 2024-02-08 US claimed
EP-4291237-A1 NOOTROPIC PEPTIDES FOR TREATING LYSOSOMAL STORAGE DISEASES Phoenix Nest Inc. (US) 2023-12-20 EP claimed
WO-2023164338-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEXUAL DYSFUNCTIONS THE JONATHAN HURT LIVING TRUST (US) 2023-08-31 WO claimed
US-20230157976-A1 HEXYLAMINE SALTS AND METHODS OF USING HEXYLAMINE THERMOLIFE INTERNATIONAL, LLC 2023-05-25 US claimed
CN-115835862-A Combination for treating alzheimer's disease and use thereof 广州新创忆药物临床研究有限公司 2023-03-21 CN claimed
US-11541020-B2 Hexylamine salts and methods of using hexylamine THERMOLIFE INTERNATIONAL, LLC (US) 2023-01-03 US claimed
US-6174890-B1 A SYNERGISTIC BIOLOGICAL, NEUROMETABOLIC AND CELLTROPHIC COMPOSITION COMPRISING ANTIOXIDATIVE AND -CATABOLIC STRESS (METHIONINE),-ANABOLIC DRUGS, VASODILATIVE AND NORMO-LIPIDEMIC DRUGS (NICOTINIC ACID), ENERGOACTIVE AND ANTITOXIC RIGA DAN (RO) 2001-01-16 US claimed
EP-1038520-A1 Cosmetics containing meclofenoxate Chabrier, Pierre-Marie (FR) 2000-09-27 EP claimed
EP-1005651-A1 METHODS OF IDENTIFYING BIOLOGICAL AGENT COMPOSITIONS SUPRATEK PHARMA, INC. (CA) 2000-06-07 EP claimed
EP-0804239-B1 ANTI-STRESS, ANTI-IMPAIRMENT AND ANTI-AGING DRUG AND PROCESS FOR MANUFACTURING THEREOF RIGA DAN (RO) 1999-09-15 EP claimed
WO-1999008112-A1 METHODS OF IDENTIFYING BIOLOGICAL AGENT COMPOSITIONS SUPRATEK PHARMA INC. (CA) 1999-02-18 WO claimed
EP-0804239-A1 ANTI-STRESS, ANTI-IMPAIRMENT AND ANTI-AGING DRUG AND PROCESS FOR MANUFACTURING THEREOF Riga, Dan (RO) 1997-11-05 EP claimed
EP-0580860-B1 METHOD OF MANUFACTURING SOLID DISPERSION NIPPON SHINYAKU CO LTD (JP) 1997-10-22 EP claimed
CN-1156410-A Anti-stress, anti-injury and anti-aging medicine and production method thereof RIGA D (RO) 1997-08-06 CN claimed
WO-1995033486-A1 ANTI-STRESS, ANTI-IMPAIRMENT AND ANTI-AGING DRUG AND PROCESS FOR MANUFACTURING THEREOF RIGA DAN (RO) 1995-12-14 WO claimed
EP-0116238-A1 Therapeutic compositions and their use in enhancing brain function BIOMEASURE, INC. (US) 1984-08-22 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11541020-B2 Hexylamine salts and methods of using hexylamine SLC6A2, CPT1B, GYS1 CYP1A2 960/4885CYP3A4 801/4885CYP2C19 657/4885
US-20230157976-A1 HEXYLAMINE SALTS AND METHODS OF USING HEXYLAMINE SLC6A2, CPT1B, GYS1 CYP1A2 960/4885CYP3A4 801/4885CYP2C19 657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.